OIS at AAO 2015


Nov 12, 2015 12:13pm ‐ Nov 12, 2015 12:21pm


PanOptica is completing a first-in-man study of PAN-90806, a novel topically administered VEGF antagonist in patients with newly diagnosed neovascular (wet) AMD. Co-founders Paul Chaney and Dr. Martin Wax lead a small, deeply experienced team and are enabled by the support of Novo Ventures, SV LifeSciences and Third Rock Ventures.


You must be logged in and own this session in order to post comments.